Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd. AstraZeneca AB UCB Pharma S.A. F. Hoffmann-La Roche Ltd Bausch Health Companies Inc. Pfizer Inc. Amgen Inc. UCB Pharma (Biogen) Bristol-Myers Squibb Company Baxalta Incorporated Eli Lilly and Company and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.